7 hrs ago
Reviewing the ketamine model for schizophrenia
The observation that antagonists of the N-methyl-D-aspartate receptor , such as phencyclidine and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia.
Trending on the Topix Network
Sat Mar 08, 2014
Stress & Schizophrenia: How to Help Your Loved One & Yourself
A common cause of relapse in schizophrenia is "difficulty managing high levels of stress," according to Susan Gingerich, MSW, a psychotherapist who works with individuals with schizophrenia and their families.
Thu Mar 06, 2014
Applied Clinical Trials
Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses.
Wed Mar 05, 2014
Pharma Sector Wants Canada Added to IP Priority List
The pharmaceutical industry is urging the Office of U.S. Trade Representative to place Canada on its intellectual property "Priority Watch List" when the agency releases the 2014 edition of its Special 301 Report in April.
Medical News Today
Community-based care helpful for schizophrenia in low-income countries
A combination of community- and facility-based treatment for schizophrenia is modestly more effective than facility-based care alone, according to new research published in The Lancet .
GABAergic interneuron origin of schizophrenia pathophysiology.
Hypofunction of N-methyl-d-aspartic acid-type glutamate receptors induced by the systemic administration of NMDAR antagonists is well known to cause schizophrenia-like symptoms in otherwise healthy subjects.
Tue Mar 04, 2014
BCC Research Publishes New Report On Global Market For Drugs Used In Mental Disorders
According to a new technical market research report Drugs for Treating Mental Disorders: Technologies and Global Markets, from BCC Research , the global market for drugs used to treat mental disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013.
New data show XEPLIONA significantly delays time to relapse compared ...
FOR MEDICAL TRADE MEDIA ONLY Janssen Pharmaceutica NV has announced results of the Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate study* at the 22 nd European Congress of Psychiatry in Munich, Germany, 1-4 March 2014.
Mon Mar 03, 2014
Should Children Take Antipsychotic Drugs?
Modern antipsychotic drugs are increasingly prescribed to children and adolescents diagnosed with a broad variety of ailments.
UPDATE 2-Roche halts study on experimental cancer drug MetMab
Roche Holding AG has halted a study of an experimental lung cancer drug because it failed to help patients with the disease, a blow for the drug which had been seen as a potential big seller as treatment options for the disease are limited.
Sun Mar 02, 2014
Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry.
Structural plasticity in the adult brain is essential for adaptive behavior. We have found a remarkable anatomical plasticity in the basal ganglia of adult mice that is regulated by dopamine D2 receptors .
Fri Feb 28, 2014
Downtown Eastside: Exhibit on mental illness spreading the NEWS
Angie Ingram spoke about her late friend from small town Alberta in a video that's part of the exhibit.
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Currently available therapeutic agents for treatment of schizophrenia target signaling by monoaminergic neurotransmitters; however, these treatments do not adequately treat the range of symptoms observed in patients.
From revolution to evolution: the glutamate hypothesis of...
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Thu Feb 27, 2014
Aberrant interference of auditory negative words on attention in patients with schizophrenia.
Previous research suggests that deficits in attention-emotion interaction are implicated in schizophrenia symptoms.
Wed Feb 26, 2014
Mental illness risk higher for children of older fathers, study indicates
Children born to middle-aged men are more likely than those born to younger fathers to develop any of a range of mental difficulties, including attention deficits, bipolar disorder, autism and schizophrenia, according to the most comprehensive study to date of paternal age and offspring mental health.
Tue Feb 25, 2014
Applied Clinical Trials
Schizophrenia Treatment Market: Novel Products to Provide Slight...
The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate of 2.4%, according to a new report from research and consulting firm GlobalData.
Applied Clinical Trials
GlobalData Releases: Schizophrenia - Global Drug Forecast and Market Analysis to 2022
A new report released by GlobalData, PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022, projects a modest increase in the global schizophrenia treatment market value.
Actigraphic registration of motor activity reveals a more structured...
Disturbances in motor activity pattern are seen in both schizophrenia and depression.
Mon Feb 24, 2014
Plan to Limit Some Drugs in Medicare Is Criticized
An alliance of drug companies and patient advocates, joined by Democrats and Republicans in Congress, is fiercely opposing an Obama administration proposal that would allow insurers to limit Medicare coverage for certain classes of drugs, including those used to treat depression and schizophrenia.